Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis
Jonathan Q Tran,1 Ahmed A Othman,2,3 Alvydas Mikulskis,4 Paul Wolstencroft,5 Jacob Elkins6 1Clinical Pharmacology, Biogen, Cambridge, MA, USA; 2Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, USA; 3Faculty of Pharmacy, Cairo University, Cairo, Egypt; 4Global Biomarker Disc...
Guardado en:
Autores principales: | Tran JQ, Othman AA, Mikulskis A, Wolstencroft P, Elkins J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/825bb9c9b25d4e2c8e4a5b15221ed180 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan S
Publicado: (2016) -
Assessing Lumbar Plexus and Sciatic Nerve Damage in Relapsing-Remitting Multiple Sclerosis Using Magnetisation Transfer Ratio
por: Ratthaporn Boonsuth, et al.
Publicado: (2021) -
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
por: Sylwia Pietrasik, et al.
Publicado: (2021) -
Promising Effects of Vitex Agnus-Castus on Quality of Life and Sexual Function in Premenopausal Relapsing Remitting Multiple Sclerosis Patients
por: Sara Rahgooy, et al.
Publicado: (2020) -
Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study
por: Konrad Rejdak, et al.
Publicado: (2021)